Immunotherapy has radically transformed the landscape of frontline treatment for advanced non-small cell lung cancer (NSCLC) without actionable mutations. Join us for this live event to hear our expert panel offer privileged insights into evidence-based guidelines for biomarker testing, the latest data pertaining to therapeutic options for NSCLC with high PD-L1 expression, and strategies to address immune-related adverse events. A patient with history of advanced NSCLC will be on the panel to augment these insights with “teaching moments” from his treatment journey.
Upon completion of this activity, participants should be better able to:
Chair and Professor, Medical Oncology
University Hospital of Lausanne
Lausanne, Switzerland
Honorary Chair, Department of Pathology
Aberdeen University School of Medicine
Aberdeen Royal Infirmary
Foresterhill
Aberdeen, Scotland, United Kingdom
Professor, Hematology and Medical Oncology
Roberto C. Goizueta Chair, Cancer Research
Director, Division of Medical Oncology
Assistant Dean, Cancer Research
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, United States
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
